| Dr Cynthia C Taub, MD | |
|
90 Presidential Plaza, Ste 5010, Syracuse, NY 13202 | |
| (315) 464-9335 | |
| (315) 464-9338 |
| Full Name | Dr Cynthia C Taub |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 31 Years |
| Location | 90 Presidential Plaza, Syracuse, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285628073 | NPI | - | NPPES |
| 001410281 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 244650 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In | 3274445796 | 242 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
By adolescence, your brain already contains most of the neurons that you'll have for the rest of your life. But a few regions continue to grow new nerve cells-and require the services of cellular sentinels, specialized immune cells that keep the brain safe by getting rid of dead or dysfunctional cells.
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.
For-profit status is associated with the extent of an outbreak of coronavirus disease 2019 (COVID-19) in long-term care (LTC) homes and the number of resident deaths from COVID-19, but not the likelihood of an outbreak, which was related to the infection rate in the surrounding local public health unit and the total number of beds in the home, found new research published in CMAJ (Canadian Medical Association Journal).
› Verified 3 days ago
| Entity Name | Department Of Medicine Medical Serv Grp At Suny Hlth Sci Ctr Syr In |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063468239 PECOS PAC ID: 3274445796 Enrollment ID: O20031104000051 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
By adolescence, your brain already contains most of the neurons that you'll have for the rest of your life. But a few regions continue to grow new nerve cells-and require the services of cellular sentinels, specialized immune cells that keep the brain safe by getting rid of dead or dysfunctional cells.
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.
For-profit status is associated with the extent of an outbreak of coronavirus disease 2019 (COVID-19) in long-term care (LTC) homes and the number of resident deaths from COVID-19, but not the likelihood of an outbreak, which was related to the infection rate in the surrounding local public health unit and the total number of beds in the home, found new research published in CMAJ (Canadian Medical Association Journal).
› Verified 3 days ago
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
By adolescence, your brain already contains most of the neurons that you'll have for the rest of your life. But a few regions continue to grow new nerve cells-and require the services of cellular sentinels, specialized immune cells that keep the brain safe by getting rid of dead or dysfunctional cells.
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.
For-profit status is associated with the extent of an outbreak of coronavirus disease 2019 (COVID-19) in long-term care (LTC) homes and the number of resident deaths from COVID-19, but not the likelihood of an outbreak, which was related to the infection rate in the surrounding local public health unit and the total number of beds in the home, found new research published in CMAJ (Canadian Medical Association Journal).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cynthia C Taub, MD 90 Presidential Plaza, Ste 5010, Syracuse, NY 13202 Ph: (315) 464-9335 | Dr Cynthia C Taub, MD 90 Presidential Plaza, Ste 5010, Syracuse, NY 13202 Ph: (315) 464-9335 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.
By adolescence, your brain already contains most of the neurons that you'll have for the rest of your life. But a few regions continue to grow new nerve cells-and require the services of cellular sentinels, specialized immune cells that keep the brain safe by getting rid of dead or dysfunctional cells.
Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International.
For-profit status is associated with the extent of an outbreak of coronavirus disease 2019 (COVID-19) in long-term care (LTC) homes and the number of resident deaths from COVID-19, but not the likelihood of an outbreak, which was related to the infection rate in the surrounding local public health unit and the total number of beds in the home, found new research published in CMAJ (Canadian Medical Association Journal).
› Verified 3 days ago
Courtney Myers, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 750 E Adams St Ste 311, Syracuse, NY 13210 Phone: 315-464-5815 | |
Joan Marie Mitchell, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-425-4828 Fax: 315-425-4827 | |
Gordana Obradovic, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1304 Buckley Rd, Suite 200, Syracuse, NY 13212 Phone: 315-478-3311 Fax: 315-476-5211 | |
Kristin A Ramella, NP Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Presidential Plz Ste 5010, Syracuse, NY 13202 Phone: 315-464-9335 | |
Vinodhini M Subramanian, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Irving Ave, Syracuse, NY 13210 Phone: 315-470-7111 | |
Robert R. Michiel, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 90 Presidential Plz, 5th Floor, Syracuse, NY 13202 Phone: 315-464-9335 Fax: 315-464-9338 | |
Michael P Gabris, MD FACC Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 E Genesee St, Suite 300, Syracuse, NY 13210 Phone: 315-471-1044 Fax: 315-474-4312 |